{
  "docId": "019de071-3aad-716d-87e6-57feca2aeaf3",
  "docSlug": "2b4775a08c8e376708f38bde257340c9",
  "documentTitle": "AstraZeneca | Results Presentation Deck | 42 slides",
  "authorId": "astrazeneca",
  "authorName": "AstraZeneca",
  "documentKindSlug": "conference-presentation",
  "documentKindLabel": "Conference presentation",
  "sourceTypeSlug": "investor_relations",
  "sourceTypeLabel": "Investor relations",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 40,
  "pageCount": 42,
  "prevPage": 39,
  "nextPage": 41,
  "slideType": "appendix_data",
  "function": "appendix",
  "density": "overcrowded",
  "nDataPoints": 12,
  "notes": "The slide uses a grid-based layout to contrast early-stage pipeline assets with late-stage and existing lifecycle management assets.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-3aad-716d-87e6-57feca2aeaf3/40",
  "deckHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3",
  "deckJsonHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3.json",
  "deckAnchorHref": "/decks/019de071-3aad-716d-87e6-57feca2aeaf3#slide-40",
  "components": [
    {
      "bbox": {
        "h": 0.08,
        "w": 0.6,
        "x": 0.02,
        "y": 0.88
      },
      "kind": "source-note",
      "text": "1. Warm autoimmune haemolytic anaemia 2. Paroxysmal nocturnal haemoglobinuria 3. Transthyretin amyloidosis... 11. Phase II basket trial.",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "0eb24141-36d2-4992-90e8-6b5a9a140372",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.65,
        "y": 0.61
      },
      "kind": "table",
      "text": "Soliris GBS; Ultomiris gMG, NMOSD, DM, ALS, HSCT-TMA, CM-TMA",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "350d8214-5fcc-4fed-8336-fd1ab483aae7",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.3,
        "x": 0.65,
        "y": 0.28
      },
      "kind": "table",
      "text": "ALXN1840 Wilson; CAEL-101 AL-amyloidosis; AG10 ATTR; ALXN2040 PNH w/EVH",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "72ba80e4-4f6b-4849-98f9-2676753085fa",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.26,
        "w": 0.47,
        "x": 0.02,
        "y": 0.43
      },
      "kind": "table",
      "text": "ALXN1720 (3rd-gen C5) gMG; ALXN1830 (anti-FcRn) gMG, WAIHA; ALXN2040 (Factor D) GA; ALXN2050 (Factor D) PNH, gMG; ALXN1820 (Anti-properdin); ALXN1850 (asfotase alfa) Hypophosphatasia",
      "attrs": null,
      "subkind": "data",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "e85d1233-9cb8-4722-a633-5fee7df9af54",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.15,
        "w": 0.6,
        "x": 0.03,
        "y": 0.04
      },
      "kind": "title",
      "text": "Appendix: Rare Diseases - 'What's next' Pipeline progress continued",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3fb0f53c-e464-4086-b1b4-93b14a43d2ef",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.03,
        "y": 0.23
      },
      "kind": "title",
      "text": "What's next Phase I/II new medicines, selected",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "2bc83432-7821-4f06-a64d-fd35b153af28",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.65,
        "y": 0.23
      },
      "kind": "title",
      "text": "What's now Phase III new medicines",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "3f03badc-b671-4a2a-bdef-ff704b97734b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.3,
        "x": 0.65,
        "y": 0.55
      },
      "kind": "title",
      "text": "Phase III lifecycle management, major",
      "attrs": null,
      "subkind": "subtitle",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "bc3a440c-2b9d-4b86-be3f-e42c3086dadb",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "Table data",
      "slug": "table-data",
      "agent": null,
      "layer": "slide",
      "matchId": "27c2ddbe-79fa-4951-88d2-0a04ae89636d",
      "evidence": "ALXN1720 (3rd-gen C5) gMG; ALXN1830 (anti-FcRn) gMG, WAIHA; ALXN2040 (Factor D) GA; ALXN2050 (Factor D) PNH, gMG; ALXN1820 (Anti-properdin); ALXN1850 (asfotase alfa) Hypophosphatasia",
      "confidence": 0.9
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}